Title:
CRYSTAL FORM OF TASIMELTEON
Document Type and Number:
WIPO Patent Application WO/2017/193662
Kind Code:
A1
Abstract:
Crystal forms I and II of tasimelteon. Crystal form I: an X-ray powder diffraction spectrum using CuKα radiation and represented by a 2θ angle has diffraction peaks at least at 7.2º±0.2º, 7.9º±0.2º, 10.6º±0.2º, 14.4º±0.2º, 15.9º±0.2º, 17.3º±0.2º, 21.0º±0.2º, 23.2º±0.2º, and 24.4º±0.2º. Crystal form II: an X-ray powder diffraction spectrum using CuKα radiation and represented by a 2θ angle has diffraction peaks at least at 6.8º±0.2º, 12.1º±0.2º, 12.5º±0.2º, 13.1º±0.2º, 13.6º±0.2º, 13.8º±0.2º, 15.8º±0.2º, 17.0º±0.2º, 18.4º±0.2º, 20.8º±0.2º, 24.2º±0.2º, and 24.4º±0.2º. Crystal forms I and II of tasimelteon have advantages of excellent physicochemical property, good stability and solubility, and simple operation for preparation.
Inventors:
ZHU JIANRONG (CN)
PENG CHUNYONG (CN)
ZHONG HONGBAN (CN)
HU XIURONG (CN)
PENG CHUNYONG (CN)
ZHONG HONGBAN (CN)
HU XIURONG (CN)
Application Number:
PCT/CN2017/074030
Publication Date:
November 16, 2017
Filing Date:
February 19, 2017
Export Citation:
Assignee:
ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D307/79; A61K31/343; A61P25/20
Domestic Patent References:
| WO2016109359A1 | 2016-07-07 |
Foreign References:
| CN105949153A | 2016-09-21 | |||
| CN103113177A | 2013-05-22 | |||
| CN104327022A | 2015-02-04 | |||
| CN1239886A | 1999-12-29 | |||
| CN102675268A | 2012-09-19 |
Other References:
DU, SHAN ET AL.: "Tasimelteon,the first new drug for the treatment of non-24-hour sleep-wake disorder in totally blind individuals", CHINESE JOURNAL OF NEW DRUGS, vol. 23, no. 12, 31 December 2014 (2014-12-31), pages 1351 - 1353 and 1389, XP055202394
Attorney, Agent or Firm:
SUNHOLD LAW FIRM (CN)
Download PDF:
Previous Patent: UV MASK DEVICE AND METHOD FOR USING THE SAME
Next Patent: METHOD FOR TREATING CARBON MONOXIDE IN AUTOMOBILE EXHAUST GAS
Next Patent: METHOD FOR TREATING CARBON MONOXIDE IN AUTOMOBILE EXHAUST GAS